Tagrisso plus chemotherapy achieves nearly four-year median overall survival in EGFR-mutated advanced lung cancer, setting new global standard in phase III trial
Fourteenth breakthrough therapy designation granted by FDA across the oncology portfolio of Daiichi Sankyo
FDA grants accelerated approval to zongertinib for HER2 TKD-Mutated Non-Squamous NSCLC
Longer-term follow up in the FLAURA2 Phase III trial confirms the favourable benefit-risk profile of this combination
ART-123 is a recombinant human thrombomodulin approved in Japan in 2008
First and only TROP2-directed therapy approved in the US for the treatment of lung cancer
The newly launched protocol will accelerate the clinical development of stenoparib and its drug-specific Drug Response Predictor (DRP) companion diagnostic (CDx) toward potential FDA approval
The decision to withdraw the BLA is based on topline overall survival (OS) results from the confirmatory HERTHENA-Lung02 Phase 3 trial where OS did not meet statistical significance
Integrated facility to deliver end-to-end, customized workflows across life sciences, diagnostics, and applied markets
Alembic Pharmaceuticals commissions new facility at Pithampur
Subscribe To Our Newsletter & Stay Updated
